Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

HYDROFLUMETHIAZIDE AND RESERPINE (HYDROFLUMETHIAZIDE; RESERPINE) | LOERadar

Viewing data from:

HYDROFLUMETHIAZIDE AND RESERPINE

ANDA

HYDROFLUMETHIAZIDE; RESERPINE | A088110 | WATSON LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Products (1)

#001 — 50MG;0.125MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Mar 22, 1983

No patent or exclusivity listings for this strength.